Deep Apple Therapeutics Eyes $812 Million Deal with Novo Nordisk
Deal News | Jun 13, 2025 | Goodwins
Deep Apple Therapeutics has entered into a significant research collaboration and exclusive worldwide license agreement with pharmaceutical giant Novo Nordisk. This partnership aims to develop and commercialize oral small molecule therapeutics targeting a novel non-incretin GPCR target for cardiometabolic diseases, such as obesity. Under the deal, Deep Apple will employ its proprietary drug discovery platform, which leverages machine learning and cryo-electron microscopy (cryo-EM), to enhance lead generation and optimization. Novo Nordisk gains exclusive rights to develop and market the compounds, with Deep Apple eligible for up to $812 million in payments, in addition to potential sales royalties. Established by Apple Tree Partners, Deep Apple has pioneered a new approach to small molecule drug discovery, intertwining structural biology and machine learning through its Orchard.ai algorithm. The company's promising pipeline targets various GPCR programs, reflecting its cutting-edge advancements. Goodwin, a law firm, advised Deep Apple in this high-profile collaboration.
Sectors
- Pharmaceuticals
- Biotechnology
Geography
- United States – Deep Apple Therapeutics, founded by Apple Tree Partners, is based in the United States, contributing to its involvement in this strategic partnership.
- Denmark – Novo Nordisk, a key collaborator in this deal, is headquartered in Denmark, emphasizing its global outreach and involvement.
Industry
- Pharmaceuticals – This industry is relevant as the article discusses a collaboration to develop and commercialize novel therapeutics for cardiometabolic diseases.
- Biotechnology – Deep Apple's role in discovering and optimizing therapeutic compounds using advanced biotechnological tools like machine learning and cryo-EM highlights the relevance of this sector.
Financials
- 812,000,000 – Total potential payments that Deep Apple Therapeutics may receive from the collaboration with Novo Nordisk.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Deep Apple Therapeutics | Target company | Company | A biotechnology firm focusing on innovative drug discovery, leveraging machine learning and cryo-EM. |
| Novo Nordisk | Bidding company | Company | A global pharmaceutical company specializing in diabetes care and other serious chronic conditions. |
| Goodwin | Legal Advisor | Company | A law firm that provided legal guidance to Deep Apple Therapeutics in the collaboration agreement. |
| Apple Tree Partners (ATP) | Investor | Company | The founding company behind Deep Apple, focusing on advancing biotech ventures. |